Protalix BioTherapeutics (PLX) Profit After Tax (2010 - 2026)

Protalix BioTherapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 606.13% year-over-year to $18.3 million in Q1 2026; TTM through Mar 2026 was $15.3 million, a 292.32% increase from a year earlier, with the FY2025 full-year figure at -$6.6 million, down 325.24% from the prior year.
• Profit After Tax advanced to $18.3 million in Q1 2026 per PLX's latest filing, from -$5.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at $19.3 million in Q2 2023 and bottomed at -$6.0 million in Q4 2023.
• The 5-year median for Profit After Tax is -$2.3 million (2022), against an average of $472352.9.
• Across the five-year window, Profit After Tax sank 184.76% in 2025 and surged 606.13% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$3.7 million in 2022, then sank by 61.6% to -$6.0 million in 2023, then jumped by 207.45% to $6.5 million in 2024, then sank by 184.76% to -$5.5 million in 2025, then jumped by 432.79% to $18.3 million in 2026.
• Per Business Quant, the three latest PLX Profit After Tax figures stand at $18.3 million (Q1 2026), -$5.5 million (Q4 2025), and $2.4 million (Q3 2025).